JP2016512564A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512564A5
JP2016512564A5 JP2016502000A JP2016502000A JP2016512564A5 JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5 JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
probenecid
improved
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512564A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/025930 external-priority patent/WO2014160153A1/en
Publication of JP2016512564A publication Critical patent/JP2016512564A/ja
Publication of JP2016512564A5 publication Critical patent/JP2016512564A5/ja
Pending legal-status Critical Current

Links

JP2016502000A 2013-03-13 2014-03-13 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療 Pending JP2016512564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361778826P 2013-03-13 2013-03-13
US61/778,826 2013-03-13
PCT/US2014/025930 WO2014160153A1 (en) 2013-03-13 2014-03-13 Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020203311A Division JP2021042248A (ja) 2013-03-13 2020-12-08 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療

Publications (2)

Publication Number Publication Date
JP2016512564A JP2016512564A (ja) 2016-04-28
JP2016512564A5 true JP2016512564A5 (https=) 2017-06-01

Family

ID=50680137

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016502000A Pending JP2016512564A (ja) 2013-03-13 2014-03-13 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療
JP2020203311A Pending JP2021042248A (ja) 2013-03-13 2020-12-08 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療
JP2023196822A Pending JP2024009140A (ja) 2013-03-13 2023-11-20 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020203311A Pending JP2021042248A (ja) 2013-03-13 2020-12-08 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療
JP2023196822A Pending JP2024009140A (ja) 2013-03-13 2023-11-20 Trpv2受容体アゴニストを用いる拡張期心機能不全の治療

Country Status (7)

Country Link
US (1) US10583103B2 (https=)
EP (1) EP2968238A1 (https=)
JP (3) JP2016512564A (https=)
AU (1) AU2014244053B2 (https=)
CA (1) CA2904671C (https=)
MX (1) MX376077B (https=)
WO (1) WO2014160153A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2017123662A1 (en) * 2016-01-11 2017-07-20 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
WO2019113685A1 (en) * 2017-12-12 2019-06-20 Cardiol Therapeutics Inc. Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
US20220401380A1 (en) * 2019-10-25 2022-12-22 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
CN115916336A (zh) * 2020-02-19 2023-04-04 施里玛·麦钱特 大麻二酚的组合物和治疗用途
KR20210150011A (ko) * 2020-06-03 2021-12-10 주식회사 삼오파마켐 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법
CN113861633B (zh) * 2021-10-14 2022-12-20 武汉工程大学 一种p-n-b阻燃pbs塑料及其制备方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524917A (en) 1969-02-10 1970-08-18 Merck & Co Inc Tablets of magnesium probenecid tetrahydrate
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPH01211582A (ja) 1988-02-16 1989-08-24 Tanabe Seiyaku Co Ltd ベンゾジオキソール誘導体
CA2115442C (en) 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
US20030212123A1 (en) 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6221856B1 (en) 1999-02-03 2001-04-24 Inologic, Inc. Inositol derivatives for inhibiting superoxide anion production
EP1317258B1 (en) 2000-06-28 2009-02-11 Merck & Co., Inc. Use of allopurinol for the treatment of hypertension
AU2001227030A1 (en) 2000-11-22 2002-06-03 Lupin Laboratories Limited Pharmaceutical composition for controlled release of an active ingredient
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
US20080051428A1 (en) 2002-05-15 2008-02-28 Davis Paul J Pyrroloquinoline quinone drugs and methods of use thereof
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
JP4679155B2 (ja) 2002-12-25 2011-04-27 キッセイ薬品工業株式会社 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
ATE405827T1 (de) 2003-09-11 2008-09-15 Takeda Pharmaceutical Screening-verfahren
DE10352511A1 (de) 2003-11-07 2005-06-16 Ernst-Moritz-Arndt-Universität Greifswald Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen
JP2007511528A (ja) 2003-11-13 2007-05-10 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム 心肥大および心不全の処置としてのtrpチャネル阻害方法
KR20060124712A (ko) 2004-02-20 2006-12-05 노파르티스 아게 신경퇴행 및 인지 장애를 치료하기 위한 dpp ⅳ 억제제
CN1950389B (zh) 2004-03-04 2011-01-19 橘生药品工业株式会社 含氮稠环衍生物,含该衍生物的药物组合物,和其作为药物的用途
EP1731524A4 (en) 2004-03-31 2009-05-20 Kissei Pharmaceutical PHENOLE DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE, AND ITS MEDICINAL USE
JP2009535410A (ja) * 2006-05-02 2009-10-01 シーエルエフ メディカル テクノロジー アクセラレーション プログラム インコーポレイテッド ピロロキノリンキノンおよびその使用
JP2009149534A (ja) 2007-12-18 2009-07-09 Japan Health Science Foundation Trpv2阻害剤,疾患の予防又は治療剤,薬剤探索用リード化合物,及び薬剤探索方法
KR100951656B1 (ko) 2008-02-25 2010-04-07 고려대학교 산학협력단 프로베네시드를 포함하는 trpv2 활성제
EP2317995B1 (en) 2008-07-17 2016-12-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2427056A4 (en) 2009-05-07 2012-08-22 Univ Cincinnati METHODS FOR PREVENTING ISCHEMIC LESION BY STIMULATION OF PERIPHERAL NICE PERIPHERAL
US10806711B2 (en) * 2011-08-12 2020-10-20 University Of Cincinnati Method of treating acute decompensated heart failure with probenecid

Similar Documents

Publication Publication Date Title
JP2016512564A5 (https=)
JP2016530280A5 (https=)
RU2016109448A (ru) Комбинированная терапия для лечения глиобластомы
FI3229828T3 (fi) Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio
JP2015518818A5 (https=)
NZ732507A (en) Improved compositions for treating muscular dystrophy
RU2017134443A (ru) Способ лечения с применением традипитанта
WO2014198852A3 (en) A dosing regime and formulations for type b adenoviruses
UA105191C2 (ru) Лечение пирфенидоном пациентов с атипической функцией печени
MY204827A (en) Semaglutide in medical therapy
RU2018123718A (ru) Режимы дозирования мелфлуфена для раковых заболеваний
MX2019002066A (es) Regimen de dosificacion para el tratamiento de tumores solidos.
AR104771A1 (es) Inhalador de polvo seco
JP2016515623A5 (https=)
JP2018531605A5 (https=)
JP2018138596A5 (https=)
RU2019107146A (ru) Схемы и способы лечения рассеянного склероза с применением офатумумаба
HK1243704A1 (zh) 用於在未接触疟疾的受试者中预防疟疾的他非诺喹的新方案
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
JP2017531042A5 (https=)
RU2015139515A (ru) Комбинированное лечение
JP2017530142A5 (https=)
FI20135503A7 (fi) Kysteiini tai sen johdannainen atrofisen gastriitin hoitamiseen
NZ760033A (en) Methods to treat opioid use disorder